August 4, 2022 09:37 AM EDTUpdated August 5, 02:03 PM
R&D
Pharma

Weeks af­ter start­ing, Am­gen flash­es yel­low light on PhI­II of $400M eczema bet

Kyle LaHucik

Senior Reporter

Am­gen is tak­ing its foot off the ped­al just a few weeks af­ter be­gin­ning a late-stage tri­al of a Ky­owa Kirin drug for which it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

GSK kicks off JPM deal­mak­ing with $1B+ buy­out of IDRx and its rare can­cer drug

J&J looks at po­ten­tial bid for In­tra-Cel­lu­lar — re­port

Bio­gen of­fers to buy out strug­gling neu­ro part­ner Sage Ther­a­peu­tics

Post-Hoc: Big Phar­ma is los­ing the AI tal­ent war

Ex­clu­sive: Buck­ing gene edit­ing down­turn, Tune rais­es $175M to bring epi­ge­net­ic edit­ing to clin­ic

Chas­ing the next wave of obe­si­ty drugs, Met­sera files for an IPO

A service from the Financial Times